Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
Type:
Grant
Filed:
October 26, 2015
Date of Patent:
July 5, 2016
Assignee:
TIGERCAT PHARMA, INC.
Inventors:
Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
December 1, 2015
Assignee:
TIGERCAT PHARMA, INC.
Inventors:
Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
Abstract: The invention relates to methods for treating pruritus with an NK-1 receptor antagonist. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonist.
Type:
Grant
Filed:
June 24, 2013
Date of Patent:
December 9, 2014
Assignee:
Tigercat Pharma, Inc.
Inventors:
Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick